A Regression Meta-Analysis for Myelopathy in Re-Irradiation of Non-Spinal Cord Tumours.
Clin Oncol (R Coll Radiol)Apr 30, 2026 (epub)
A Salem, L Alsaloumi, S Althyabat et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis examined the incidence of radiation-induced myelopathy following reirradiation of non-spinal cord tumors, analyzing 43 studies with 2527 patients. It found a significant dose-response relationship, with each 10 Gy² increase in cumulative biologically effective dose (BED) associated with a 9.3% increase in myelopathy risk. The study highlights the importance of dose constraints and treatment intervals in reirradiation planning.
Key findings
- Baseline incidence of myelopathy after photon reirradiation was 0.009% (95% CI: 0.001-8.58%).
- Patients with myelopathy had a mean cumulative BED of 140 Gy² compared to 100 Gy² for those without (p < 0.001).
- Each additional month between reirradiation courses reduced myelopathy odds by 16% (OR=0.84, 95% CI: 0.77-0.91, p < 0.0001).
- Proton reirradiation studies reported zero myelopathy events despite a mean cumulative BED of 170.2 Gy².
Why it matters
Understanding the dose-response relationship for myelopathy risk is crucial for clinicians involved in radiation therapy, as it informs treatment planning and patient safety measures during reirradiation.